Access to anti-retroviral drugs, male in Angola

Angola: Access to anti-retroviral drugs, male was 52.0% in 2024. ◆ Volatile

Latest (2024)
52.0%
Change on year
up 8.3%
World rank
113th
of 141 countries
All-time high
52.0%
in 2024
All-time low
0.0%
in 2000
Years of data
25
2000–2024

Access to anti-retroviral drugs, male in Angola, 2000–2024

02040602000201220242000: 0 %2001: 0 %2002: 0 %2003: 0 %2004: 0 %2005: 0 %2006: 3 %2007: 5 %2008: 8 %2009: 10 %2010: 13 %2011: 15 %2012: 16 %2013: 19 %2014: 22 %2015: 26 %2016: 28 %2017: 32 %2018: 34 %2019: 31 %2020: 34 %2021: 39 %2022: 43 %2023: 48 %2024: 52 %

Source: UNAIDS estimates. Measured in %.

Analysis

The most recent figure for access to anti-retroviral drugs, male in Angola is 52.0%, measured in 2024. That is the highest value across all 25 years on record.

That represents a change of up 8.3% on the previous year and up 136.4% over ten years.

Over the whole period, access to anti-retroviral drugs, male in Angola peaked at 52.0% in 2024 and was at its lowest, 0.0%, in 2000.

Angola ranks 113th of 141 countries on this measure, in the bottom quarter.

The series is highly variable year to year, so single readings are best treated with caution.

Access to anti-retroviral drugs, male in Angola, year by year

Annual values for Access to anti-retroviral drugs, male (%) in Angola, 2000 to 2024.
Year % Change
2000 0.0%
2001 0.0%
2002 0.0%
2003 0.0%
2004 0.0%
2005 0.0%
2006 3.0%
2007 5.0% +66.7%
2008 8.0% +60.0%
2009 10.0% +25.0%
2010 13.0% +30.0%
2011 15.0% +15.4%
2012 16.0% +6.7%
2013 19.0% +18.8%
2014 22.0% +15.8%
2015 26.0% +18.2%
2016 28.0% +7.7%
2017 32.0% +14.3%
2018 34.0% +6.2%
2019 31.0% -8.8%
2020 34.0% +9.7%
2021 39.0% +14.7%
2022 43.0% +10.3%
2023 48.0% +11.6%
2024 52.0% +8.3%

Averages by decade

DecadeAverage LowestHighest Years
2000s 2.6% 0.0% 10.0% 10
2010s 23.6% 13.0% 34.0% 10
2020s 43.2% 34.0% 52.0% 5

Countries ranked near Angola

  1. 110 Niger 56.0% compare
  2. 110 Senegal 56.0% compare
  3. 112 Bahrain 53.0% compare
  4. 113 Armenia 52.0% compare
  5. 113 South Sudan 52.0% compare
  6. 116 Latvia 51.0% compare

See the full ranking of 160 places →

More gender data for Angola

All data for Angola →

Frequently asked questions

What is access to anti-retroviral drugs, male in Angola?
Access to anti-retroviral drugs, male in Angola was 52.0% in 2024, according to UNAIDS estimates.
What is the highest access to anti-retroviral drugs, male recorded in Angola?
The highest recorded value was 52.0% in 2024.
What is the lowest access to anti-retroviral drugs, male recorded in Angola?
The lowest recorded value was 0.0% in 2000.
How does Angola rank for access to anti-retroviral drugs, male?
Angola ranks 113th out of 141 countries with data for 2024.
Is access to anti-retroviral drugs, male rising or falling in Angola?
Over the last ten years it is up 136.4%. The long-run trend across the full record is volatile.
Where does this Angola data come from?
The figures come from UNAIDS estimates, published as part of Access to anti-retroviral drugs, male (%). Statizoid updates them automatically from the source API.

Download this data

CSV · JSON — 25 observations, free to reuse under CC BY 4.0 (World Bank Open Data).

Share, cite or embed this page

Cite this page

Access to anti-retroviral drugs, male in Angola. Statizoid, drawing on UNAIDS estimates. Retrieved 09 September 2026, from https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-male-percent/angola/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY 4.0 (World Bank Open Data); please keep the attribution.

<a href="https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-male-percent/angola/">Access to anti-retroviral drugs, male in Angola</a> — Statizoid

About this data

Indicator
Access to anti-retroviral drugs, male (%)
Unit
%
Source
UNAIDS estimates
Licence
CC BY 4.0 (World Bank Open Data)
Coverage
160 places, 3,923 data points, 2000–2024
Last refreshed

The percentage of adult males living with HIV who are receiving antiretroviral therapy.